KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis
Experimental & Molecular Medicine
;
: 502-508, 2006.
Artículo
en Inglés
| WPRIM
| ID: wpr-181049
ABSTRACT
Angiogenesis is considered to be an integral process to the growth and spread of solid tumors. Anti-angiogenesis therapy recently has been found to be one of the most promising anti-cancer therapeutic strategies. In this study, we provide several lines of evidences showing that KR-31831, a new benzopyran derivative, has anti-angiogenic activities. KR-31831 inhibited the proliferation, migration, invasion and tube formation of bovine aortic endothelial cells (BAECs), and suppressed the release of matrix metalloproteinase-2 (MMP-2) of BAECs. KR-31831 also inhibited in vivo angiogenesis in mouse Matrigel plug assay. Furthermore, the mRNA expressions of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor-2 (FGFR-2), and vascular endothelial growth factor receptor-2 (VEGFR-2) were decreased by KR-31831. Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Benzopiranos
/
Movimiento Celular
/
Células Cultivadas
/
Factor 2 de Crecimiento de Fibroblastos
/
Neovascularización Fisiológica
/
Metaloproteinasa 2 de la Matriz
/
Inhibidores de la Angiogénesis
/
Receptor 2 de Factores de Crecimiento Endotelial Vascular
/
Células Endoteliales
/
Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos
Tipo de estudio:
Estudio pronóstico
Límite:
Animales
Idioma:
Inglés
Revista:
Experimental & Molecular Medicine
Año:
2006
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS